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Abstract Stably transfected HEK-293 cells express on their
surface the murine type II IL-1 receptor (mIL-1RII) as
demonstrated by FACS analysis using the mAb 4E2, however
binding of [125I]-hrIL-1L to these cells is nearly absent. Saturable
high affinity binding of [125I]-hrIL-1L is observed when the
murine IL-1 receptor accessory protein (mIL-1RAcP) is coex-
pressed with mIL-1RII. Binding of [125I]-hrIL-1L to mIL-1RII-
mIL-1RAcP complex can be inhibited either with antibodies to
mIL-1RII (mAb 4E2), or by antibodies to mIL-1RAcP (mAb
4C5). The number of high affinity binding sites in cells stably
transfected with the cDNA for mIL-1RII is dependent on the
dose of cDNA for mIL-1RAcP used to transfect the cells. The
high affinity complex between mIL-1RII and mIL-1RAcP is not
preformed by interaction between the intracellular domains of
these two transmembrane proteins, rather it appears to require
the extracellular portions of mIL-1RII and mIL-1RAcP and the
presence of a ligand. We suggest that in addition to its earlier
described decoy receptor role, IL-1RII may modulate the
responsiveness of cells to IL-1 by binding the IL-1RAcP in
unproductive/non-signalling complexes and thus reducing the
number of signalling IL-1RI-IL-1RAcP-agonist complexes when
IL-1 is bound.
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1. Introduction
The cytokine interleukin-1 (IL-1) is a mediator of immune
and in£ammatory responses (for review, see [1]). The ‘inter-
leukin-1 system’ possesses three ligands, two receptor sub-
types, and one receptor accessory protein, respectively. The
IL-1 receptor agonists, IL-1K and IL-1L, have overlapping
biological activities, which can be blocked by excess of the
endogenously occurring IL-1 receptor antagonist (IL-1ra)
[2]. Two IL-1 receptor subtypes have been cloned from mam-
malian cells : the 80 kDa type I receptor (IL-1RI), and the 68
kDa type II receptor (IL-1RII) [3,4]. The discovery of the
murine IL-1 receptor accessory protein (mIL-1RAcP) as a
part of a signalling IL-1 receptor-ligand complex was long
awaited as most functional cytokine receptors form oligomeric
complexes [5]. It has been shown that the IL-1RI can form a
complex with IL-1RAcP in the presence of agonists but not in
the presence of the antagonist [5]. The IL-1RI and the IL-
1RAcP have both been shown to be essential for IL-1 medi-
ated signalling in vivo and in vitro [6^9]. However, there is a
¢nding also suggesting that there is IL-1-IL-1RI induced neu-
tral sphingomyelinase activity that is independent of the IL-
1RAcP [8]. In binding assays the IL-1RII has been shown to
act as an high a⁄nity IL-1 binding protein, without any sub-
sequent intracellular signalling to occur [10]. IL-1RII is
shedded from the cell upon IL-1 stimulation [11] and an alter-
natively processed IL-1RII has also been described [12], pro-
viding in addition to the membrane bound, non-signalling IL-
1RII, a soluble decoy target for IL-1 agonists. Until now, no
information on an interaction of IL-1RAcP with IL-1RII has
been presented.
Here we describe that the membrane bound mIL-1RII has
an absolute requirement for the presence of mIL-1RAcP, for
the high a⁄nity binding of hrIL-1L. In addition we present
data suggesting that the interaction between mIL-1RII and
mIL-1RAcP is not involving the intracellular portions of these
proteins.
2. Materials and methods
2.1. Eukaryotic expression constructs
The cDNA encoding the murine IL-1RII was subcloned from
pRep3/mIL-1RII (kindly provided by Dr. J.E. Sims) into the pcDNAI
vector (Invitrogen). The pcDNAI/mIL-1RAcP, for expression of the
mIL-1RAcP, was obtained by RT-PCR from total RNA isolated
from the murine hypothalamic GT1-7 cell line. The resultant cDNA
fragment was cloned, sequenced, and digested with restriction en-
zymes and shown to yield the expected restriction fragment sizes.
2.2. Cell culture and transfection
Human embryonic kidney ¢broblast cell line (HEK-293, ATCC)
was grown in MEM supplemented with 10% (v/v) foetal bovine se-
rum, L-glutamine, 50 Wg/ml gentamycin, 100 Wg/ml penicillin/strepto-
mycin. For transfection experiments cells were grown in 100 mm cell
culture dishes until 60% con£uency. Cells were transfected by a Ca-
phosphate method using 20 Wg of plasmid as described [13], and
harvested within 24^48 h. To generate HEK-293 cells stably express-
ing the mIL-1RII, transiently transfected cells were transferred to
medium supplemented with 300 Wg/ml geneticin (G418, Life Technol-
ogies) and allowed to grow an additional two weeks before clones
were isolated.
2.3. [125I]-hrIL-1L binding to whole cells
Transfected HEK-293 cells were harvested and washed once in
binding bu¡er (RPMI 1640; 25 mM HEPES, pH 7.2; 1% BSA (w/
v); 0.1% NaN3 (w/v)). The cells were incubated with 50 pM [125I]-
hrIL-1L (speci¢c activity 150 WCi/Wg, DuPont, NEN, Boston, MA) in
the absence or presence of 100 nM unlabelled hrIL-1L as competitor.
To demonstrate selective expression of receptor subtypes blocking
mAb 4C5, anti-mIL-1RAcP 10 Wg/ml and blocking mAb 4E2, anti-
mIL-1RII 3.5 Wg/ml (kindly provided by Dr. R. Chizzonite) were
used. Displacement curves were generated by incubating transfected
HEK-293 cells with 50 pM [125I]-hrIL-1L and varying concentrations
of hrIL-1L. Free ligand was separated from bound by centrifugation
as described [14]. Protein concentration was determined using the
Lowry protein assay [15] with BSA as standard.
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2.4. Western blots
HEK-293 cell extracts (150 Wg of protein), in non-reducing loading
dye were separated on a 10% (w/v) SDS-PAGE, and blotted onto
Nylon membranes (Amersham). The membranes were incubated
with 0.35 Wg/ml of the mAb 4E2 (rat anti-mIL-1RII), rabbit anti-
rat-FITC (Daco A/S, Denmark, dilution 1:1000), and goat anti-rab-
bit-AP (Sigma, dilution 1:1000), respectively.
2.5. Facs analysis
HEK-293 cells and HEK-293 cells stably transfected with mIL-
1RII-cDNA, were transiently transfected either with pcDNAI/mock
vector or pcDNAI/mIL-1RAcP vector as described. Transfected cells
were washed with PBS, 1 mM EDTA pH 7.45, incubated in non-
enzymatic cell dissociation solution (Sigma) at 37‡C, and washed
twice in cold PBS pH 7.45, 0.05% (w/v) NaN3 before incubation
with or without mAb 4E2 (anti-mIL-1RII, 3.5 Wg/ml). mAb 4E2 bind-
ing was detected by incubation with rabbit anti-rat-FITC (Daco A/S,
Denmark, dilution 1:100 or 1:1000). The cells were washed twice in
PBS pH 7.45, 0.05% (w/v) NaN3, before FACS analysis.
2.6. Two hybrid IL-1R expression plasmids
The intracellular (ic) portion of the mIL-1RII, encoding aa 383^411
(icmIL-1RII), and the mIL-1RAcP, encoding aa 384^570 (icmIL-
1RAcP), were obtained by RT-PCR. Total RNA were isolated from
murine AtT-20 and murine GT1-7 cell lines, respectively. The resul-
tant cDNA fragments were cloned into both the pGBT9 and the
pGAD424 plasmids, sequenced and digested with restriction enzymes
and shown to yield the expected restriction fragment sizes.
2.7. Yeast two hybrid screening
The yeast SFY526 (Clontech) reporter strain was utilised for the
two hybrid studies according to the supplier’s instructions. LacZ re-
porter gene transactivation was assayed of yeast colonies lifted from
agar plates using Whatman No 1 ¢lter paper quickly frozen in liquid
nitrogen, and ¢nally put on a ¢lter paper submerged with phosphate
bu¡ered X-gal solution (pH 7.0, 0.33 Wg/ml). The experiments were
performed three times.
3. Results and discussion
The human kidney HEK-293 cells were transiently trans-
fected with cDNA encoding the mIL-1RII, mIL-1RAcP, or
cotransfected with both cDNAs. It is shown in Fig. 1A that
cells transfected with the mIL-1RII-cDNA express a very low
amount of [125I]-hrIL-1L binding sites as compared to mIL-
1RII/mIL-1RAcP-cDNA cotransfected cells. HEK-293 cells
transfected with only mIL-1RAcP-cDNA did not bind [125I]-
hrIL-1L. The requirement of coexpression and complex for-
mation between mIL-1RII and the mIL-1RAcP for the bind-
ing is further demonstrated by the inhibition of the [125I]-
hrIL-1L binding by antibodies directed against either the
mIL-1RII (mAb 4E2) or by the antibodies directed against
mIL-1RAcP (mAb 4C5), (Fig. 1A). The stoichiometric com-
plex formation between the mIL-1RII and the mIL-1RAcP is
further supported by the dose dependent appearance of spe-
ci¢c [125I]-hrIL-1L binding capacity when cells which are sta-
bly transfected and expressing the mIL-1RII, are transfected
with increasing amounts of cDNA for mIL-1RAcP (Fig. 1B).
We found that HEK-293 cells coexpressing mIL-1RII and
mIL-1RAcP bind hrIL-1L with an IC50 of 2.5 þ 0.1 nM
(n = 3) which is similar to the a⁄nity for hrIL-1L of mIL-
1RII on the murine pre-B-cell line 70Z/3 [3]. The 70Z/3 cell
line endogenously expresses mRNAs for both the mIL-1RII
and the mIL-1RAcP [16]. The very small amount of [125I]-
hrIL-1L binding sites upon mIL-1RII-cDNA transfection
(Fig. 1A), which accounts to less than 10% of total binding
obtained when compared to mIL-1RII/mIL-1RAcP-cDNA
cotransfected cells was blocked by the mAb 4E2 (data not
shown).
To further investigate the role of mIL-1RAcP in the bind-
ing of hrIL-1L by the mIL-1RII, HEK-293 cells stably ex-
pressing the mIL-1RII (293-RII) were generated. The level
of mIL-1RII expression in 293-RII cells was examined both
by Western blot and FACS analysis using mAbs (4E2) to the
mIL-1RII. It is shown in Fig. 2A that transient transfection
with mIL-1RAcP-cDNA of 293-RII cells does not alter the
level of mIL-1RII expression as compared to pcDNAI trans-
fection. To examine whether the mIL-1RII is expressed on the
cell surface in the absence of the IL-1RAcP we examined the
stably transfected 293-RII cells under conditions of transfec-
tion with pcDNAI or mIL-1RAcP-cDNA. Fig. 2B present
FACS data showing that the same amount of immunoreactive
mIL-1RII is expressed on the cell surface, both in the absence
and presence of the mIL-1RAcP. Even though expression of
mIL-1RAcP did not alter cell surface expression of the mIL-
1RII, a more than 20-fold increase in the number of [125I]-
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Fig. 1. Binding and inhibition of binding of [125I]-hrIL-1L to the
HEK-293 cell line expressing mIL-1RII and mIL-1RAcP. A: Specif-
ic binding data are shown for [125I]-hrIL-1L binding to HEK-293
cells transiently transfected with the indicated cDNAs (+). Inhibi-
tion of binding of [125I]-hrIL-1L by the mAb 4E2 to mIL-1RII (3.5
Wg/ml) and the mAb 4C5 to mIL-1RAcP (10 Wg/ml) is shown. 100%
speci¢c binding was de¢ned as the speci¢c binding to mIL-1RII/
mIL-1RAcP-cDNA cotransfected HEK-293 cells and corresponds to
0.8 þ 0.3 fmol bound [125I]-hrIL-1L/mg protein. Results are the
mean þ S.D. of three independent experiments each based on dupli-
cates. B: [125I]-hrIL-1L binding by HEK-293 cells stably transfected
with mIL-1RII-cDNA. Stably transfected cells were transiently
transfected with 20 Wg plasmid of graded concentrations of mIL-
1RAcP-cDNA (0, 1, 5, and 20 Wg). The ¢gure is the mean þ S.D. of
two independent experiments each based on duplicates.
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hrIL-1L binding sites was observed in cells expressing both
mIL-1RII and mIL-1RAcP (Fig. 1B). This means that the
IL-1RII alone has an a⁄nity lower than that detectable by
us using 50 pM [125I]-hrIL-1L as tracer.
Equilibrium binding experiments by McMahan and col-
leagues showed that the Kd of [125I]-hrIL-1L for the recombi-
nant mIL-1RII such as expressed on the green monkey ¢bro-
blast-like cell line CV1/EBNA was 20 nM [3]. Furthermore,
using 300 pM of [125I]-hrIL-1L as tracer in displacement bind-
ing experiments, 20% of the speci¢c bound [125I]-hrIL-1L
could be displaced by hrIL-1L with an IC50 of 1.25 nM, while
80% of the bound [125I]-hrIL-1L was displaced with an
IC50s 100 nM [3]. Gene transfer studies using human IL-
1RII-cDNA [12,17] suggest that the low a⁄nity of the hrIL-
1L to the membrane bound mIL-1RII on HEK-293 cells is
due to species speci¢c di¡erences in receptor a⁄nity. How-
ever, since the expression levels of the IL-1RAcP usually are
not investigated, it is still possible that membrane IL-1RII in
general, have low a⁄nity for the IL-1 family of ligands in the
absence of the IL-1RAcP.
We also examined whether the IL-1RII-IL-1RAcP complex
required for hrIL-1L binding is preformed ^ in the absence of
an agonist ^ through direct interaction between the intracel-
lular domains of the transmembrane receptors. Using the
yeast two hybrid system we could not detect any interactions
between the intracellular portions of IL-1RII and IL-1RAcP
(Table 1). Neither did we detect any interaction between IL-
1RII receptors or IL-1RAcPs that would suggest dimerisation
of these in absence of their extracellular domains and/or in the
absence of the agonist (Table 1). Control experiments showed
clearly that the two hybrid system functions (Table 1).
We have performed similar cotransfection experiments on
HEK-293 cells as those in Fig. 1A, using cDNA for the mIL-
1RI and the mIL-1RAcP, respectively and found that the type
I IL-1R (IL-1RI) can bind [125I]-hrIL-1L with an IC50 of
1.6 þ 0.2 nM (n = 3) and when the cells also express the IL-
1RAcP the binding a⁄nity increases (IC50 0.5 þ 0.2 nM)
(n = 3). Thus we con¢rm earlier published data showing that
the IL-1 binding to the mIL-1RI is possible in the absence of
the mIL-1RAcP [18], and that presence of mIL-1RAcP will
increase the a⁄nity of the mIL-1RI for hrIL-1L approxi-
mately 5-fold [5]. This fact is of importance evaluating the
signi¢cance of the present ¢ndings, since our data show that
for binding of an agonist to the IL-1RII the presence of an
IL-1RAcP is required, thus the IL-1RII will compete with the
IL-1RI for IL-1RAcP in the presence of an agonist and there-
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Table 1
Intracellular IL-1R interactions in the yeast two hybrid system
icIL-1RII pGBT9 icIL-1RAcP pGBT9 pVA3
icIL-1RII pGAD424 3 3 -
icIL-1RAcP pGAD424 3 3 -
pTD1 - - +
The intracellular portion of the mIL-1RII (aa 383^411) and of mIL-1RAcP (aa 384^570) was expressed as fusion proteins with the GAL4 DNA
binding (encoded in pGBT9) and transcriptional activation (encoded in pGAD424) domains, respectively. Interactions between intracellular
portions of mIL-1RII and IL-1RAcP were measured as lacZ reporter gene activity. pVA3 and pTD1 are control plasmids supplied by the
manufacturer, which yielded positive signal. The experiments were performed three times.
Fig. 2. Expression of the mIL-1RII by HEK-293 cells stably trans-
fected with the mIL-1RII-cDNA. A: Western blot using the mAb
4E2 (anti-mIL-1RII). HEK-293 cells stably transfected with mIL-
1RII-cDNA (293-RII) were transiently transfected with the indicated
cDNAs (+). Control wild-type HEK-293 cells (293) transiently co-
transfected with the indicated cDNAs (+) do not express mAb 4E2
immunoreactive protein (mIL-1RII). Arrow indicates 68 kDa. B:
FACS analysis of the mIL-1RII cell surface expression using the
mAb 4E2. The rat mAb 4E2 binding was visualised by incubation
with rabbit anti rat-FITC (Daco A/S, Denmark). HEK-293 cells sta-
bly transfected with the mIL-1RII-cDNA were transiently trans-
fected with mock vector pcDNAI (solid line) or mIL-1RAcP-cDNA
(dashed line). mIL-1RAcP-cDNA transfected cells, incubated with-
out mAb 4E2, is shown in shaded. Control HEK-293 cells trans-
fected and incubated as above showed no immunoreactivity with
mAb 4E2 (data not shown).
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by may decrease the number of signalling IL-1RI-IL-1RAcP
complexes per cell, and dampen the response to IL-1 agonists.
This is an additional mode of modulating IL-1 signalling via
the IL-1RII.
It is interesting to note that the cross-linking studies on
soluble IL-1RII-IL-1 complexes suggest that the soluble type
II IL-1R (sIL-1RII) does bind the agonist in the absence of
the extracellular domain of the IL-1RAcP [17], thus it appears
that while anchored to the membrane, the IL-1RII modulates
signalling both via availability of the IL-1RAcP and via bind-
ing IL-1 agonists. The relative importance of the shedding of
the IL-1RII and of the complexing and sequestering the IL-
1RAcP is not possible to determine from these studies in
absence of data on the endogenous abundance of IL-1RI,
IL-1RII and the IL-1RAcP, respectively and without data
on the relative a⁄nities of the IL-1RI and IL-1RII for the
IL-1RAcP. Our data show qualitatively that cell surface ex-
pressed IL-1RII may act to inhibit the IL-1 signalling via
binding the IL-1RAcP.
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